M&A activity in the liquid biopsy space is picking up as Bio-Techne said it will acquire Exosome Diagnostics for $250 million plus $325 million in potential milestones.
Diagnostics manufacturers and even medical device innovators can play roles, says an expert working to raise awareness.
Freenome has initiated a clinical study to help bring an AI-Genomics blood test for colorectal cancer to the U.S. market.
Grail raises $300 million in Series C round to give massive boost to the development of its liquid biopsy applications for cancer.
A new study shows proposed changes in the International Classification of Diseases (ICD) guidelines could lead to a reduction in the diagnosis of PTSD patients.
Myriad Genetics presented results from a 24-week study that showed Major Depressive Disorder patients were 50% more likely to achieve remission and 30% more likely to respond to treatment using the GeneSight Psychotropic genetic test.
Orion Diagnostica develops Point-of-Care tests and earned about $67 million in sales for its most recent reported year.
Bristol-Myers Squibb has teamed up with Illumina to develop companion diagnostics for oncology immunotherapies.
Qiagen has developed liquid biopsy panels for prostate and lung cancer and is set to introduce the products at the American Association for Cancer Research annual meeting this week.
These seven medtech companies aren't just moving the needle, they're getting rid of it all together!
A new study has confirmed the accuracy of the Xpresys Lung 2 test developed by Integrated Diagnostics.
Qiagen, known for its oncology offerings, is set to develop assays for the non-invasive prenatal testing market through a $40 million collaboration with Natera.